

# WEST Search History

**[Hide Items](#)** **[Restore](#)** **[Clear](#)** **[Cancel](#)**

DATE: Sunday, February 08, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=USPT; PLUR=NO; OP=OR</i>			
<input type="checkbox"/>	L35	L34 and (mmp)	1
<input type="checkbox"/>	L34	l28 and (lysozyme)	27
<input type="checkbox"/>	L33	L28 and (mmp adj 1)	2
<input type="checkbox"/>	L32	L28 and (mmp adj 12)	0
<input type="checkbox"/>	L31	L28 and (mmp adj 12)	0
<input type="checkbox"/>	L30	L28 and l10	0
<input type="checkbox"/>	L29	L28 and l6	0
<input type="checkbox"/>	L28	L27 and l24	116
<input type="checkbox"/>	L27	l20 and l3	296
<input type="checkbox"/>	L26	l20 and l2	0
<input type="checkbox"/>	L25	l14 and l20	0
<input type="checkbox"/>	L24	l20 and l1	652
<input type="checkbox"/>	L23	L22 l20 and l1	656
<input type="checkbox"/>	L22	L20 and (l11 or l10 or l9 or l7)	4
<input type="checkbox"/>	L21	L20 and (l11 or l10 or l9 or l7 or l1 or l2 or l3)	836
<input type="checkbox"/>	L20	(inflammatory adj bowel adj disease) or ibd	4893
<input type="checkbox"/>	L19	L11 and l10 and l9 and l7	0
<input type="checkbox"/>	L18	L11 and l10	0
<input type="checkbox"/>	L17	L16 and l6	0
<input type="checkbox"/>	L16	l14 and l3	1
<input type="checkbox"/>	L15	L14 and l2	0
<input type="checkbox"/>	L14	l11 and l1	1
<input type="checkbox"/>	L13	L11 and l10	0
<input type="checkbox"/>	L12	L11 and l10 and l9 and l7 and l6	0
<input type="checkbox"/>	L11	(max adj interacting adj protein adj 1) or mxii	9
<input type="checkbox"/>	L10	(down adj regulated adj in adj rhabdosarcoma) or dra1	115
<input type="checkbox"/>	L9	calgizzarin	9
<input type="checkbox"/>	L8	calgizzatin	0
<input type="checkbox"/>	L7	dd96	4
<input type="checkbox"/>	L6	dra or (down adj regulated adj adenoma)	913
<input type="checkbox"/>	L5	gos2	16

<input type="checkbox"/>	L4	(phospholipase adj a2 adj group adj iia) or pla2g2a	8
<input type="checkbox"/>	L3	metallothionein	5003
<input type="checkbox"/>	L2	(growth adj hormone adj 2) or gh2	139
<input type="checkbox"/>	L1	(il adj 8) or mdncf	2299

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 11:15:17 ON 08 FEB 2004)

FILE 'MEDLINE, SCISEARCH' ENTERED AT 11:16:02 ON 08 FEB 2004

FILE 'MEDLINE, CAPLUS, SCISEARCH' ENTERED AT 11:16:26 ON 08 FEB 2004

L1        28428 S INFLAMMATORY BOWEL DISEASE  
L2        30656 S L1 OR IBD  
L3        16 S L2 AND IL8  
L4        2823 S IP-10  
L5        544 S (GROWTH HORMONE 2) OR GH2  
L6        108 S GRO1  
L7        32 S GRO2  
L8        432 S (NEUTROPHIL LIPOCALIN) OR HNL  
L9        23714 S METALLOTHIONEIN  
L10      36 S DD96 OR (EPITHELIAL PROTEIN UPREGULATED IN CARCINOMA)  
L11      92 S CALGIZZARIN  
L12      156 S DRAL OR (DOWN REGULTED IN RHABDOSARCOMA)  
L13      12 S MAX INTERACTING PROTEIN 1  
L14      0 S L2 AND L13 AND L12 AND L11 AND L10 AND L9  
L15      1 S L2 AND L13

FILE 'STNGUIDE' ENTERED AT 11:23:05 ON 08 FEB 2004

FILE 'MEDLINE, SCISEARCH, CAPLUS' ENTERED AT 11:26:31 ON 08 FEB 2004

L16      5 S L2 AND L12  
L17      19 S L2 AND L4  
L18      0 S L17 AND L9  
L19      1 S L17 AND L5  
L20      1 S L17 AND IL8  
L21      29 S L2 AND IL6  
L22      0 S L21 AND L9  
L23      2 S L21 AND MMP  
L24      49 S L2 AND MICROARRAY#

FILE 'GENBANK' ENTERED AT 11:40:21 ON 08 FEB 2004

L25      2 S Y00787  
L26      34 S X54489  
L27      2 S M57731  
L28      2 S M28130  
L29      36 S J03756  
L30      1 S S75256  
L31      2 S X99133  
L32      1 S X85781  
L33      3 S X65965  
L34      114 S M22430  
L35      1 S X51441  
L36      1 S J03474  
L37      9 S M21119  
L38      53 S D00408  
L39      46 S D14662

FILE 'CAPLUS' ENTERED AT 11:43:49 ON 08 FEB 2004

L40      0 S L39 AND L38 AND L37 AND L36 AND L35 AND L34  
L41      0 S L39 AND L38 AND L37 AND L36 AND L35  
L42      0 S L39 AND L38 AND L37 AND L36  
L43      0 S L39 AND L38 AND L37  
L44      0 S L39 AND L38 AND L37 AND (L36 OR L35 OR L34)  
L45      0 S L39 AND L38 AND (L37 OR L36 OR L35 OR L34)  
L46      9 S L39  
L47      1 S L46 AND L2  
L48      0 S L38 AND L2

L49 0 S L37 AND L2  
L50 0 S L37 AND L2  
L51 0 S L36 AND L2  
L52 0 S L35 AND L2  
L53 0 S L34 AND L2  
L54 0 S L33 AND L2  
L55 0 S L25 AND L2  
L56 0 S L26 AND L2  
L57 0 S L27 AND L2  
L58 1 S L28 AND L2  
L59 0 S L29 AND L2  
L60 0 S L30 AND L2  
L61 0 S L31 AND L2  
L62 0 S L31 AND L2  
L63 0 S L33 AND L2  
E LAWRENCE IAN C/AU  
E FIOCCHI CLAUDIO/AU  
L64 6 S E1  
L65 50 S E3  
L66 0 S L64 AND L65  
L67 56 S L64 OR L65  
L68 34 S L67 AND L2  
L69 1 S L68 AND MICROARRAY#  
L70 1 S L69  
L71 1 S L68 AND HNL  
L72 1 S NGAL AND L68  
E LAWRENCE IAN C/AU  
L73 2 S E3  
E CHAKRAVARTI SHUKTI/AU  
L74 4 S E3 AND L2

=>

L68 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521277 CAPLUS  
DN 125:192733  
ED Entered STN: 30 Aug 1996  
TI Interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**  
AU Matsuura, Toshihiro; Kusugami, Kazuo; Morise, Kimitomo; **Fiocchi, Claudio**  
CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan  
SO Cytokines in Inflammatory Bowel Disease (1996), 41-56. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review  
LA English  
CC 15-0 (Immunochemistry)  
AB A review, with 98 refs. The authors discuss interleukin-2 activity by intestinal mucosal mononuclear cells in **inflammatory bowel disease (IBD)**, soluble interleukin-2 receptor production by lamina propria mononuclear cells, lymphokine-activated killer cell activity in **IBD**, and levels of IL-2 and IL-2R mRNA in **IBD**.  
ST review interleukin 2 **inflammatory bowel disease**  
IT Intestine, disease  
    (inflammatory, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)  
IT Lymphokines and Cytokines  
    RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
    (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)  
IT Lymphokine and cytokine receptors  
    Receptors  
    RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)  
    (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)

L68 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521279 CAPLUS  
DN 125:192735  
ED Entered STN: 30 Aug 1996  
TI Interleukin-6 in **inflammatory bowel disease**  
AU Kusugami, Kazuo; Morise, Kimitomo; Shinoda, Masataka; Haruta, Jun-ichi; Tanimoto, Mitsune  
CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan  
SO Cytokines in Inflammatory Bowel Disease (1996), 69-83. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review  
LA English  
CC 15-0 (Immunochemistry)  
AB A review, with 89 refs. Based on the multitude of biol. functions of IL-6 on essentially all tissues and cells in the body, this cytokine has also attracted much attention in the pathogenesis of **inflammatory bowel disease (IBD)** under the assumption that dysregulation of IL-6 activity may be associated with immune abnormalities in patients with ulcerative colitis and Crohn's disease. This paper discusses IL-6 in **IBD**, keeping in mind that the investigation of

IL-6 in **IBD** patients to clarify its involvement in the pathogenesis and perpetuation of **IBD** is still in progress.

ST review interleukin 6 **inflammatory bowel disease**

IT Intestine, disease  
(inflammatory, interleukin-6 in **inflammatory bowel disease**)

IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(interleukin 6, interleukin-6 in **inflammatory bowel disease**)

L68 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521281 CAPLUS  
DN 125:192737  
ED Entered STN: 30 Aug 1996  
TI Chemotactic cytokines (chemokines) in **inflammatory bowel disease**  
AU MacDermott, Richard P.; Izutani, Ryo; Ohno, Yasuhiro; Reinecker, Hans-Christian  
CS Gastroenterology Section, Lahey Clinic, Burlington, MA, USA  
SO Cytokines in Inflammatory Bowel Disease (1996), 101-118. Editor(s): Fiocchi, Claudio. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review  
LA English  
CC 15-0 (Immunochemistry)  
AB A review with 102 refs. The presence of large nos. of granulocytes and macrophages in the bowel wall is a common feature in **inflammatory bowel disease (IBD)**. Granulocytes and macrophages are thought to contribute to the immunopathogenesis of **IBD**. The constant flux of granulocytes and macrophages indicates the likely presence of potent chemotactic agents in inflamed intestinal mucosa. The regulation of granulocyte and macrophage movement into inflamed mucosal and submucosal tissue may also be mediated by chemokines, which are potent mediators of granulocyte and macrophage migration and activation. Two of the chemokines, interleukin-8 and monocyte chemotactic and activating factor (MCAF) are likely to have important roles in mediating chronic intestinal inflammation in diseases such as **IBD**

ST review chemokine **inflammatory bowel disease**

IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(chemokines, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

IT Intestine, disease  
(inflammatory, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

L68 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521282 CAPLUS  
DN 125:192738  
ED Entered STN: 30 Aug 1996  
TI The colony-stimulating factors in **inflammatory bowel disease**  
AU Doe, William F.; Grimm, Michael C.  
CS John Curtin Sch. Clinical Res., Australian natl. Univ., Canberra City, Australia  
SO Cytokines in Inflammatory Bowel Disease (1996), 119-136. Editor(s): Fiocchi, Claudio. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review

LA English  
CC 15-0 (Immunochemistry)  
AB A review, with 65 refs. The authors discuss the biol. activities of each of the colony-stimulating factors (CSFs), their potential roles and synergies in immune and inflammatory responses and the potential effects of these functions on the regulation and mediation of mucosal inflammation in **inflammatory bowel disease (IBD)**).  
ST review colony stimulating factor bowel disease  
IT Intestine, disease  
    (inflammatory, colony-stimulating factors in **inflammatory bowel disease**)  
IT 62683-29-8, Colony-stimulating factor  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
    (colony-stimulating factors in **inflammatory bowel disease**)  
  
L68 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521283 CAPLUS  
DN 125:192063  
ED Entered STN: 30 Aug 1996  
TI Peptide growth factors in **inflammatory bowel disease**  
AU Dignass, Axel U.; Podolsky, Daniel K.  
CS Dep. Med., Univ. Essen, Essen, Germany  
SO Cytokines in Inflammatory Bowel Disease (1996), 137-155. Editor(s):  
    Fiocchi, Claudio. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review  
LA English  
CC 14-0 (Mammalian Pathological Biochemistry)  
AB A review, with 76 refs., of general properties of prototypic peptide growth factors which are likely to be important in **inflammatory bowel disease** including EGF, TGF- $\alpha$ , TGF- $\beta$ , IGF, FGF, HGF, CSF, and trefoil factors.  
ST review growth factor **inflammatory bowel disease**  
IT Animal growth regulators  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
    (peptide growth factors in **inflammatory bowel disease**)  
IT Intestine, disease  
    (inflammatory, peptide growth factors in **inflammatory bowel disease**)  
  
L68 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:547943 CAPLUS  
DN 125:219585  
ED Entered STN: 13 Sep 1996  
TI Cytokines in **Inflammatory Bowel Disease**.  
AU Fiocchi, Claudio; Editor  
CS USA  
SO (1996) Publisher: (Landes, Austin, Tex.), 265 pp.  
DT Book  
LA English  
CC 15-8 (Immunochemistry)  
    Section cross-reference(s): 14  
AB Unavailable  
ST book cytokine **inflammatory bowel disease**  
IT Lymphokines and Cytokines  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
    (Biological study); PROC (Process)

(cytokines in **inflammatory bowel disease**)  
IT Intestine, disease  
(inflammatory, cytokines in **inflammatory bowel disease**)

L68 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521276 CAPLUS  
DN 125:192732  
ED Entered STN: 30 Aug 1996  
TI Interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**  
AU Kam, Lori; Cominelli, Fabio  
CS Div. Gastrointestinal Liver Diseases, Univ. Southern California Sch. Med., Los Angeles, CA, USA  
SO Cytokines in Inflammatory Bowel Disease (1996), 27-39. Editor(s): **Fiocchi, Claudio.** Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH  
DT Conference; General Review  
LA English  
CC 15-0 (Immunochemistry)  
AB A review, with 36 refs. Immune cells and their cytokines are likely to play an important role in the initiation and perpetuation of the chronic inflammation associated with ulcerative colitis and Crohn's disease. Activated mononuclear cells produce interleukin-1 (IL-1), a pro-inflammatory cytokine with multiple biol. properties that may be responsible for the initiation and amplification of the inflammatory response. Macrophage activation has been hypothesized to be an early event in the pathogenesis of intestinal bowel disease (**IBD**). This suggests that IL-1 is also involved in the early events of the inflammatory cascade. This paper reviews the role of IL-1 and IL-1ra in **IBD**, and discusses new strategies for treatment of **IBD** based on the modulation of IL-1 activity.  
ST review interleukin 1 **inflammatory bowel disease**  
IT Intestine, disease  
(inflammatory, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)  
IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(interleukin 1, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)  
IT Lymphokines and Cytokines  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(interleukin 1 receptor antagonist, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)